Repatha vs. Livalo

See how Repatha and Livalo compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Repatha is an injectable PCSK9 inhibitor given every two weeks or monthly, while Livalo is a daily oral statin, so the two lower cholesterol through very different mechanisms and routines.

  • Repatha has outcomes-trial evidence for cutting heart attacks and strokes, while Livalo is a statin without its own dedicated outcomes trial, though off-label use for prevention is common.

  • Both drugs lower LDL cholesterol, but Repatha's injection typically costs more per month while Livalo's pill carries the classic statin risks of muscle pain and rare liver effects.

Repatha vs. Livalo Drug Summary

Repatha

Repatha (evolocumab) is a PCSK9 inhibitor given as a subcutaneous injection to lower LDL cholesterol and reduce cardiovascular risk in adults with heart disease or genetic high cholesterol. It's injected every two weeks or once a month, depending on the dose prescribed.

Livalo

Livalo (pitavastatin) is a statin that lowers LDL cholesterol as an add-on to diet in adults with high cholesterol or genetic high cholesterol. It's taken as a once-daily tablet, with doses ranging from 1 mg to 4 mg.

Repatha vs. Livalo Side Effects

Repatha

Most common
nasopharyngitis (up to 10.5%)
upper respiratory tract infection (up to 9.3%)
influenza (up to 7.5%)
back pain (up to 6.2%)

Livalo

Most common
myalgia (1.9% to 3.1%)
constipation (1.5% to 3.6%)
diarrhea (1.5% to 2.6%)
back pain (1.4% to 3.9%)

Repatha vs. Livalo Dosage

Repatha

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 140 mg every 2 weeks At the start
Maximum dose 420 mg every 2 weeks If needed
Dose changes 2 increases As tolerated

Livalo

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 1 mg once daily At the start
Maximum dose 4 mg once daily If needed
Dose changes 2 increases As tolerated

Repatha vs. Livalo Indications

Repatha

Repatha is FDA-approved to reduce the risk of heart attack, stroke, and certain heart procedures in adults with established cardiovascular disease. It's also approved to lower LDL cholesterol in people with heterozygous or homozygous familial hypercholesterolemia, including children as young as 10.

  • Reduce risk of heart attack and stroke in adults with heart disease

  • Lower LDL in heterozygous familial hypercholesterolemia (add-on)

  • Lower LDL in homozygous familial hypercholesterolemia (add-on)

  • Approved for children 10 and older with familial hypercholesterolemia

Livalo

Livalo is FDA-approved as an add-on to diet to lower LDL cholesterol, total cholesterol, and triglycerides in adults with primary hyperlipidemia or mixed dyslipidemia. It's also approved for heterozygous familial hypercholesterolemia, including children 8 and older, and is sometimes used off-label for primary prevention of atherosclerotic heart disease.

  • Lower LDL and triglycerides in adults with high cholesterol

  • Lower LDL in heterozygous familial hypercholesterolemia

  • Approved for children 8 and older with familial hypercholesterolemia

  • Off-label: primary prevention of atherosclerotic heart disease

Repatha vs. Livalo Pros and Cons

Repatha

Repatha offers strong, trial-proven cardiovascular protection delivered through an antibody injection rather than a daily pill. It costs more than most oral statins and has no biosimilar yet, so insurance coverage and prior authorization often shape access.

Pros

  • Injected every two weeks or once monthly, no daily pill needed

  • Outcomes trial (FOURIER) showed fewer heart attacks and strokes

  • Approved for pediatric familial hypercholesterolemia starting age 10

  • No liver-related contraindications like active liver disease

Cons

  • Requires injection, which some patients find less convenient

  • Roughly $580 to $730 per month before insurance, more than Livalo

  • No biosimilar competition yet, keeping the price elevated

  • Can cause injection site reactions

Livalo

Livalo works like other statins to lower LDL cholesterol through a once-daily tablet with a long safety track record. It costs less than Repatha but carries the typical statin risks of muscle pain and, rarely, liver problems.

Pros

  • Oral tablet taken once daily, no injections involved

  • Roughly $315 to $410 per month before insurance, less than Repatha

  • Minimal CYP3A4 metabolism means fewer drug interactions than many statins

  • Long-standing safety record since its 2009 approval

Cons

  • Carries risk of myopathy and rare rhabdomyolysis, needing monitoring

  • Contraindicated with cyclosporine and dose-limited with some antibiotics

  • Not approved for children under age 8

  • No dedicated cardiovascular outcomes trial of its own

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.